Optimized Cardioprotection Therapy in Obese Subjects With AMI
Effects and Mechanism of Adipokines Cardiac Protection in Obese Patients With Acute Myocardial Infarction (AMI) Who Have Undergone Percutaneous Coronary Intervention (PCI).
1 other identifier
observational
120
1 country
1
Brief Summary
The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With acute myocardial infarction (AMI) Who Have Undergone Percutaneous Coronary Intervention (PCI).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 25, 2020
CompletedFirst Posted
Study publicly available on registry
September 30, 2020
CompletedStudy Start
First participant enrolled
October 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2020
CompletedSeptember 30, 2020
September 1, 2020
Same day
September 25, 2020
September 25, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of patient death during the follow up period
1 year
Secondary Outcomes (7)
Left ventricular ejection fraction
1 year
Myocardial perfusion scores as evaluated by Single-photon emission computed tomography (SPECT)
1 year
Infarct size as evaluated by Single-photon emission computed tomography (SPECT)
1 year
Number of target vessel revascularization
1 year
Angina class according to the canadian cardiovascular society (CCS) classification
1 year
- +2 more secondary outcomes
Study Arms (2)
Obesity
Patients with Obesity. BMI\>=25
Non-Obesity
Patients without Obesity. BMI\<25
Interventions
Eligibility Criteria
Patients of AMI were enrolled in this study.
You may qualify if:
- age between 20 and 70 years old STEMI and NSTMI according to the WHO definition PCI \<12 hours from the onset of symptoms
You may not qualify if:
- previous myocardial infarction (MI) cardiomyopathy atrial fibrillation or flutter previous heart surgery severe valvular heart disease disease of the hematopoietic system NYHA functional class IV heart failure at baseline severe renal, lung and liver disease cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xijing Hospitallead
Study Sites (1)
Xijing hospital
Xi'an, Shaanxi, 710032, China
Biospecimen
Serum, Plasma
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dongdong Sun, M.D.,Ph.D
Xijing Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Cardiology department
Study Record Dates
First Submitted
September 25, 2020
First Posted
September 30, 2020
Study Start
October 1, 2020
Primary Completion
October 1, 2020
Study Completion
December 30, 2020
Last Updated
September 30, 2020
Record last verified: 2020-09